IPO Timeline Raw facts
Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 迈威生物 |
|---|---|
| Other Market Stock Code | 688062 |
| H-Share Offer Price | HK$ 27.64 |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Mabwell-B |
|---|---|
| Stock Code | 02493 |
| Company Full Name | Mabwell (Shanghai) Bioscience Co., Ltd. |
| Industry | Healthcare |
| Principal Activities | We are a Chinese pharmaceutical company known for our innovation capabilities in drug research and development as well as our end-to-end capabilities from drug discovery to commercialization. We primarily focus on the independent development of drugs in areas such as oncology, immunology, ophthalmology, and orthopedics. We have established a pipeline product portfolio comprising 4 marketed products and 10 drug candidates of different varieties (1 at the NDA stage, 8 at the clinical stage, and 1 at the preclinical stage), including a self-developed core product 9MW2821 (an ADC candidate targeting Nectin-4). |
| Listing Date | 2026-04-28 |
| Listing Rules Era | New Rules (after Aug 2025) |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市中國(上海)自由貿易試驗區蔡倫路230號2幢105室 |
| Business Address (Hong Kong) | 香港銅鑼灣希慎道33號利園一期19樓1928室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.mabwell.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | Yes (A股) |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 27.64 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 5,528 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2026-04-20 to 2026-04-23 |
| Global Offering Shares | 47,130,200 shares |
| HK Public Offer Shares (Initial) | 4,713,200 shares (10.0%) |
| Public Offer Lots (Initial) | 23,566lots (Pool A11,783lots,Pool B11,783lots) |
| International Placing Shares (Initial) | 42,417,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 446,730,200 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 31.9% |
| Clawback Tiers | Mechanism B: no clawback |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 1,302,678,728 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 5,528 |
| 2 lots | 400 | HK$ 11,056 |
| 3 lots | 600 | HK$ 16,584 |
| 4 lots | 800 | HK$ 22,112 |
| 5 lots | 1,000 | HK$ 27,640 |
| 6 lots | 1,200 | HK$ 33,168 |
| 7 lots | 1,400 | HK$ 38,696 |
| 8 lots | 1,600 | HK$ 44,224 |
| 9 lots | 1,800 | HK$ 49,752 |
| 10 lots | 2,000 | HK$ 55,280 |
| 15 lots | 3,000 | HK$ 82,920 |
| 20 lots | 4,000 | HK$ 110,560 |
| 25 lots | 5,000 | HK$ 138,200 |
| 30 lots | 6,000 | HK$ 165,840 |
| 35 lots | 7,000 | HK$ 193,480 |
| 40 lots | 8,000 | HK$ 221,120 |
| 45 lots | 9,000 | HK$ 248,760 |
| 50 lots | 10,000 | HK$ 276,400 |
| 100 lots | 20,000 | HK$ 552,800 |
| 150 lots | 30,000 | HK$ 829,200 |
| 200 lots | 40,000 | HK$ 1,105,600 |
| 250 lots | 50,000 | HK$ 1,382,000 |
| 300 lots | 60,000 | HK$ 1,658,400 |
| 350 lots | 70,000 | HK$ 1,934,800 |
| 400 lots | 80,000 | HK$ 2,211,200 |
| 450 lots | 90,000 | HK$ 2,487,600 |
| 500 lots | 100,000 | HK$ 2,764,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 200,000 | HK$ 5,528,000 |
| 1,500 lots | 300,000 | HK$ 8,292,000 |
| 2,000 lots | 400,000 | HK$ 11,056,000 |
| 2,500 lots | 500,000 | HK$ 13,820,000 |
| 3,000 lots | 600,000 | HK$ 16,584,000 |
| 3,500 lots | 700,000 | HK$ 19,348,000 |
| 4,000 lots | 800,000 | HK$ 22,112,000 |
| 4,500 lots | 900,000 | HK$ 24,876,000 |
| 5,000 lots | 1,000,000 | HK$ 27,640,000 |
| 10,000 lots | 2,000,000 | HK$ 55,280,000 |
| 11,783 lots | 2,356,600 | HK$ 65,136,424 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 953.5M |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 12,347,622,728 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 1,302,678,728 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not applicable (loss-making) |
| Profit/Loss Status | Net loss RMB 972.3 million |
| Period-End Cash Balance | RMB 1,191.9 million |
| Listing Expenses | ~HK$ 119,400,000 |
| Listing Expenses / Funds Raised | ~8.7% |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 27.8 |
|---|---|
| First Day Open | HK$ 28.3 |
| First Day Change | 0.58% |
| First Day Volume | 15006500.0 |
| First Day Turnover | 424940000.0 |
| Use of Proceeds | 1、約56.8%,或713.0百萬港元將用于核心產品9MW2821針對多種適用癥不同階段的臨床開發試驗;
2、約17.7%,或222.3百萬港元將用于針對具有大量臨床需求的腫瘤和年齡相關疾病的其他管線產品的研發;
3、約15.5%,或194.7百萬港元將用于商業化目的;
4、約10.0%,或125.6百萬港元將用于營運資金及其他一般公司用途。 |
Underwriting Syndicate
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
Davis Polk & Wardwell 竞天公诚律师事务所 霍金路伟律师行 |
| Legal Advisor to Sponsors/Underwriters |
Herbert Smith Freehills Kramer 金杜律师事务所 |
| Auditor and Reporting Accountant | 安永会计师事务所 |
| Industry Advisor | 弗若斯特沙利文(北京)咨询有限公司上海分公司 |
| Compliance Advisor | Somerley Capital Limited CE BAU754 |
| Receiving Banks |
中国银行(香港)有限公司 招商永隆银行有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 君实香港 | 20,000,000 USD | 5,668,200 | 12.03% | 1.27% | 6 months | 2026-10-28 |
| 2 | Sanjin International | 15,000,000 USD | 4,251,200 | 9.02% | 0.95% | 6 months | 2026-10-28 |
| 3 | 国惠香港 | 7,000,000 USD | 1,983,800 | 4.21% | 0.44% | 6 months | 2026-10-28 |
| 4 | 昌荣国际 | 7,000,000 USD | 1,983,800 | 4.21% | 0.44% | 6 months | 2026-10-28 |
| 5 | WuXi Biologics Venture | 3,000,000 USD | 850,200 | 1.80% | 0.19% | 6 months | 2026-10-28 |
| 6 | 中和资本 | 1,000,000 USD | 283,400 | 0.60% | 0.06% | 6 months | 2026-10-28 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 劉大濤 | — |
| Company Secretary | 王鶴飛 | — |
| Executive Director | 唐春山 | TANG Chunshan |
| Non-Executive Director | 吴玉峰 | WU Yufeng |
| Independent Non-Executive Director | 秦正余 | QIN Zhengyu |
| Executive Director | 刘大涛 | LIU Datao |
| Independent Non-Executive Director | 许青 | XU Qing |
| Executive Director | 武海 | WU Hai |
| Independent Non-Executive Director | 赵倩 | ZHAO Qian |
| Executive Director | 胡会国 | HU Huiguo |
| Independent Non-Executive Director | 王芳 | WANG Fang |
| Executive Director | 桂勋 | GUI Xun |
Major Shareholders
| Major Shareholders & Holdings | As of the Latest Practicable Date, Mr. Tang (i) directly owned approximately 79.92% of the partnership interest in Longrun Equity as a limited partner and indirectly owned 0.10% of the partnership interest in Longrun Equity through Longrun Investment Consulting as a general partner, and Longrun Equity beneficially owned 140,560,000 A Shares; (ii) directly owned approximately 2.12% of the partnership interest in Zhongjun Jianlong as a general partner, and Zhongjun Jianlong beneficially owned 20,000,000 A Shares; (iii) directly owned approximately 10.56% of the partnership interest in Zhenzhu Investment as a general partner, and Zhenzhu Investment beneficially owned 6,800,000 A Shares; and (iv) directly owned 88.30% of the equity interest in Longrun Investment Consulting, and Longrun Investment Consulting beneficially owned 2,000,000 A Shares. Under the Securities and Futures Ordinance, Mr. Tang is deemed to be interested in the shares held by Longrun Equity, Zhongjun Jianlong, Zhenzhu Investment, and Longrun Investment Consulting. |
|---|
Market Sentiment
The IPO of 迈威生物-B saw overwhelming retail enthusiasm with a 481.71x oversubscription ratio. Despite the high demand, the hit rate is reported as 0.0%, likely reflecting extremely low allocation under the no-clawback mechanism. This signals fierce competition for shares among small investors. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
At the A-Tail tier, 100,000 applicants expected just 0.3204 lots each, while the B-Head tier offered a full 1.0 lot per applicant for 200,000 applicants. This stark difference highlights an inefficiency where the marginal capital required to jump from A-Tail to B-Head dramatically improves allocation certainty. Broker fee efficiency likely favors larger applications, though actual costs vary. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Mainland Chinese participants accounted for 54.9% of total holders, indicating strong cross-border interest in this biotech listing. The investor base skews male (62.2%) with an average age of 43.2, typical for high-risk 18A biotech plays. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)




